Astellas Pharma Inc
ALPMY
|
News
|
$9.49
-1.11%
480K
|
Manufacturing
(0.0% 1d) (-14.4% 1m) (-36.2% 1y) (0.0% 2d) (-0.2% 3d) (-0.3% 7d) (-16.73% volume)
Earnings Calendar:
Market Cap: $ 17,173,702,582
https://www.astellas.com/jp/
Sec Filling | Patents | n/a employees
(JP)
add to watch list Paper trade email alert is off
Press-releases
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Published: 2024-04-23 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -1.05%
H: 0.85%
C: 0.85%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.19%
H: 0.08%
C: -0.68%
granted approval cancer treatment for
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
Published: 2024-04-22 (Crawled : 09:00) - prnewswire.com
SMFNF | News | $55.63 -1.2% 24K
|
Finance
|
| O: -0.16%
H: 3.14%
C: 0.04%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 0.63%
H: 0.0%
C: -0.31%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.8%
H: 0.75%
C: 0.38%
drug company for agreement
Prostate Cancer: Advancements in Prevention and Treatment Drive Global Market Growth
Published: 2024-04-17 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
treatment global growth market
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
ALPMF | News | $9.5 43.47% 1.2K
|
Health Technology
|
| O: -3.69%
H: 5.08%
C: 5.08%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -1.31%
H: 2.95%
C: 2.08%
IFRX | $1.355 -0.37% -0.37% 71K
|
Health Technology
|
| O: -4.17%
H: 2.17%
C: -5.07%
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: 1.61%
H: 0.79%
C: -8.73%
Usher Syndrome Market to Exhibit Growth at a CAGR of 10.55% by 2034 | DelveInsight
Published: 2024-04-11 (Crawled : 22:00) - prnewswire.com
ALPMF | News | $9.5 43.47% 1.2K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -8.65%
H: 3.19%
C: 1.6%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.65%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.0%
H: 0.52%
C: -1.04%
growth market
Central Nervous System (CNS) Stimulant Drugs Market size is set to grow by USD 6.48 billion from 2023-2027, Rise in incidence of CNS disorders boost the market, Technavio
Published: 2024-04-10 (Crawled : 09:00) - prnewswire.com
ALPMF | News | $9.5 43.47% 1.2K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: -1.67%
H: 0.0%
C: 0.0%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -0.29%
H: 0.0%
C: -1.97%
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -0.6%
H: 1.03%
C: 0.52%
TMO | News | $577.39 0.49% 0.0% 2M
|
Health Technology
|
| O: -2.01%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -1.16%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: -1.71%
H: 0.57%
C: 0.37%
disorders system set market
Gene Therapies in Ophthalmology Market to Register Immense Growth at a CAGR of 57.8% by 2034 | DelveInsight
Published: 2024-04-04 (Crawled : 22:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -0.52%
H: 0.71%
C: 0.71%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.84%
H: 0.0%
C: 0.0%
SLDB | $8.75 -3.95% -4.11% 140K
|
Health Technology
|
| O: -0.73%
H: 1.3%
C: -1.06%
growth market
Retinitis Pigmentosa Market to Grow Rapidly at a CAGR of 16.8% by 2034 | DelveInsight
Published: 2024-04-02 (Crawled : 22:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -0.65%
H: 2.43%
C: -0.28%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
market
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-03-28 (Crawled : 15:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 0.82%
H: 0.0%
C: -2.54%
keytruda license bladder cancer treatment medical application advanced
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
Published: 2024-03-26 (Crawled : 12:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -1.65%
H: 3.36%
C: 3.17%
japan approved cancer treatment
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10